Integra Lifesciences Holdings (IART) Total Debt (2009 - 2026)

Integra Lifesciences Holdings (IART) has 18 years of Total Debt data on file, last reported at $755.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt fell 35.27% year-over-year to $755.6 million; the trailing twelve-month figure through Mar 2026 stood at $755.6 million (down 35.27% YoY), and the FY2025 full-year result was $1.8 billion, up 6.45% from the prior year.
• Total Debt retreated to $755.6 million in Q1 2026, from $1.8 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $1.8 billion in Q4 2025 to a low of $755.6 million in Q1 2026.
• A 5-year average of $1.0 billion and a median of $869.6 million in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt soared 100.39% in 2024 and slumped 54.54% in 2025, its largest moves.
• Tracing IART's Total Debt over 5 years: stood at $837.8 million in 2022, then gained by 0.27% to $840.1 million in 2023, then soared by 97.73% to $1.7 billion in 2024, then gained by 6.45% to $1.8 billion in 2025, then slumped by 57.27% to $755.6 million in 2026.
• Business Quant data shows IART's Total Debt at $755.6 million in Q1 2026, $1.8 billion in Q4 2025, and $775.0 million in Q3 2025.